Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008;3:e2557. [PMID: 18596939 DOI: 10.1271/journal.pone.0002557]

Association between miRNA-146a rs2910164 gene polymorphism and susceptibility to colorectal cancer: A systematic review

AIM: To accurately evaluate the association between the miRNA-146a rs2910164G/C polymorphism and susceptibility to colorectal cancer.

METHODS: An electronic search of PubMed, Excerpta Medica Database (Embase), Chinese Biomedical Literature Database (CBM), the Cochrane Library, Weipu and Wanfang Database was performed to collect all the publications investigating the association between miR-146a rs2910164G/C polymorphism and risk of colorectal cancer. We then analyzed the differences in miRNA-146a rs2910164G/C genotypes (G vs C, GG vs CC, GG vs GC, GC vs CC, GG + GC vs CC, GG vs GC + CC) between cases and controls by meta-analysis.

RESULTS: Seven studies involving 2978 cases and 3576 controls were found to be eligible for meta-analysis. We summarized the data on the association between miR-146a rs2910164G/C polymorphism and risk of colorectal cancer in the overall population. In the overall analysis, there was no evidence for an association between the miR-146a rs2910164 polymorphism and the risk of colorectal cancer (G vs C: OR = 0.82, 95%CI: 0.52-1.30, P = 0.41; GG vs CC: OR = 1.10, 95%CI: 0.72-1.40, P = 0.97; GG vs GC: OR = 1.10, 95%CI: 0.81-1.28, P = 0.91; GC vs CC: OR = 0.99, 95%CI: 0, 70-1.41, P = 0.96; GG + GC vs CC: OR = 1.00, 95%CI: 0.72-1.39, P = 0.99; GG vs GC + CC: OR = 1.00, 95%CI: 0.81-1.24, P = 0.98).

CONCLUSION: This meta-analysis demonstrated that the miR-146a rs2910164 polymorphism is not associated with colorectal cancer susceptibility.